Emerging biologics in severe asthma

Documents similaires

• Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
  par: Shrimanker, R, et autres
  Publié: (2017)
• Evidence for the efficacy and safety of anti- interleukin-5 treatment in the management of refractory eosinophilic asthma
  par: Xue, L, et autres
  Publié: (2015)
• Management and mechanisms of severe eosinophilic asthma
  par: Shrimanker, R
  Publié: (2020)
• Exacerbations of severe asthma in patients treated with mepolizumab
  par: Shrimanker, R, et autres
  Publié: (2018)
• Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
  par: Howell, I, et autres
  Publié: (2024)